High-dose antithrombin III treatment of severely injured patients: Results of a prospective study

Journal of Trauma - Injury, Infection and Critical Care

Volumn 45, Issue 5, 1998, Pages 931-940

  Waydhas, Christian ^a,b   Nast Kolb, Dieter ^a   Gippner Steppert, Cornelia ^a   Trupka, Arnold ^a   Pfundstein, Christoph ^a   Schweiberer, Leonhard ^a   Jochum, Marianne ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antithrombin III; Cytokines; Disseminated intravascular coagulation; Multiple injuries; Multiple organ failure; Neutrophils; SIRS; Systemic inflammatory response syndrome; Wounds and injuries

Indexed keywords

ANTITHROMBIN III; HEPARIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR RECEPTOR;

ACIDOSIS; ADULT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEPARINIZATION; HUMAN; INFLAMMATION; INJURY SCALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 0031728553     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199811000-00015     Document Type: Conference Paper

References (45)

1. Büller HR, TenCate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med. 1989;87(suppl 3B):44.
2. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol. 1991; 28:10.
3. Owings JT, Bagley M, Gosselin R, et al. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J Trauma. 1996;41:396.
4. Engelman DT, Gabram SGA, Allen L, et al. Hypercoagulability following multiple trauma. World J Surg. 1996;20:5.
5. Wilson RF, Mammen EF, Tyburski JG, et al. Antithrombin levels related to infections and outcome. J Trauma. 1996; 40:384.
6. Miller RS, Weatherford DA, Stein D, et al. Antithrombin III and trauma patients: factors that determine low levels. J Trauma. 1994;37:442.
7. Nast-Kolb D, Waydhas C, Jochum M, et al. Biochemical factors as an objective parameter in assessing injury severity and prognosis in polytrauma patients. Unfallchirurg. 1992; 95:59.
8. Nast-Kolb D, Waydhas C, Gippner-Steppert C, et al. Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries. J Trauma. 1997;42:446.
9. Waydhas C, Nast-Kolb D, Jochum M, et al. Inflammatory mediators, infection, sepsis, and multiple organ failure after severe trauma. Arch Surg. 1992;127:460.
10. Pizzo SV. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med. 1989;87(suppl 3B):10.
11. Jordan RE, Nelson RM, Kirkpatrick J, et al. Inactivation of human antithrombin by neutrophil elastase. J Biol Chem. 1989;264:10493.
12. Jordan RE, Kirkpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by elastase. Science. 1987; 237:777.
13. Bone RC. Sepsis syndrome: new insights in the pathogenesis and treatment. Intensive Crit Dig. 1990;10:50.
14. Jacob HS, Wickham NW, Vercellotti GM. Platelet-activating factor as facilitator of immune response: its role in priming inflammatory and endothelial cells. In: Braquet P, ed. Platelet Activating Factor and Cell Immunology: New Trends in Lipid Mediator Research. Basel, Switzerland: Karger Verlag; 1988:130.
15. Hebert CA, Luscinskas FW, Kiely JM, et al. Endothelial and leukocyte forms of IL-8. J Immunol. 1990;145:3033.
16. Lo SK, Lai L, Cooper JA, et al. Thrombin-induced generation of neutrophil activating factors in blood. Am J Pathol. 1988;130:22.
17. Manwaring D, Curreri PW. Platelet and neutrophil sequestration after fragment D-induced respiratory distress Circ Shock. 1982;9:75.
18. Johnson A, Garcia-Szabo R, Kaplan JE, et al. Fibrin degradation products increase lung transvascular fluid filtration after thrombin-induced pulmonary microembolism. Thromb Res. 1985;37:543.
19. Luterman A, Manwaring D, Curreri PW. The role of fibrinogen degradation products in the pathogenesis of the respiratory distress syndrome. Surgery. 1977;82:703.
20. Saldeen T. Clotting, microembolism, and inhibition of fibrinolysis in adult respiratory distress. Surg Clin North Am. 1983;63:285.
21. Okajima K. New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure. Intensivmedizin. 1996;33:5.
22. Uchiba M, Okajima K, Murakami K, et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996;270:L931.
23. Yamauchi T, Umeda F, Inoguchi T, et al. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989; 163:1404.
24. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59:895.
25. Emerson TE, Fournel MA, Redens TB, et al. Efficacy of antithrombin III supplementation in animal models of fulminant E. coli endotoxemia or bacteremia. Am J Med 1989;87(suppl 3B):27.
26. Emerson TE, Fournel MA, Leach WJ, et al. Protection against disseminated intravascular coagulation and death by antithrombin III in the E. coli endotoxemic rat. Circ Shock. 1987;21:1.
27. Taylor FB, Emerson TE, Jordan R, et al. Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock. 1988;26:227.
28. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemostasis. 1993; 69:98.
29. Blauhut B, Kramar H, Vinazzer H, et al. Substitution of antithrombin III in shock and DIC: a randomized study Thromb Res. 1985;39:81.
30. Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 1993;104:882.
31. The Abbreviated Injury Scale. 1990 revision. Des Plaines, Ill: Association for the Advancement of Automotive Medicine; 1990.
32. Baker SP, O'Neill B, Haddon W, et al. The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974; 14:187.
33. Trupka A, Waydhas C, Nast-Kolb D, et al. Early intubation in severely injured patients. Eur J Emerg Med. 1994;1:1.
34. Blauhut B, Necek S, Vinazzer H, et al. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res. 1982;27:271.
35. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med. 1994;20:225.
36. Moore FA, Sauaia A, Moore EE, et al. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma. 1996; 40:501.
37. Neely AN, Miller RG, Holder IA. Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition. Infect Immun. 1994; 62:2158.
38. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemostasis. 1989;15:347.
39. Vinazzer HA. Antithrombin III in shock and disseminated intravascular coagulation. Clin Appl Thromb Hemostasis. 1995;1:62.
40. Lamy M, Eisele B, Keinecke HO, et al. Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind multicenter trial. In: Proceedings of the 9th European Congress on Intensive Care Medicine, Glasgow, UK. Bologna, Italy: Monduzzi Editore; 1996:385.
41. Inthorn D. Therapie mit Proteinaseinhibitoren: Antithrombin III. In: Schuster HP, ed. Intensivtherapie bei Sepsis und Multiorganversagen. Berlin, Germany: Springer Verlag; 1993:91.
42. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol. 1995;32(suppl 2):19.
43. Diaz-Cremades JM, Lorenzo R, Sanchez M, et al. Use of antithrombin III in critical patients. Intensive Care Med 1994;20:577.
44. Uchiba M, Okajima K, Murakami K, et al. Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. Thromb Res. 1995;78:117.
45. Cohen JR, Sarfati I, Birnbaum E, et al. The inactivation of antithrombin III by serum elastase in patients with surgical infections. Am Surg. 1990;56:665